Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

1,050.00USD
--
Change (% chg)

-- (--)
Prev Close
$1,050.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7
52-wk High
$1,100.00
52-wk Low
$788.70

Select another date:

Tue, Aug 15 2017

Bristol-Myers kidney cancer drug fails late-stage trial

Bristol-Myers Squibb Co said on Tuesday its combination drug to treat previously untreated patients with advanced or metastatic renal cell carcinoma, a type of kidney cancer, failed to meet one of the main goals of a late-stage trial.

UPDATE 1-Bristol-Myers kidney cancer drug fails late-stage trial

Aug 15 Bristol-Myers Squibb Co said on Tuesday its combination drug to treat previously untreated patients with advanced or metastatic renal cell carcinoma, a type of kidney cancer, failed to meet one of the main goals of a late-stage trial.

Bristol-Myers kidney cancer drug fails late-stage trial

Aug 15 Bristol-Myers Squibb Co said on Tuesday its combination drug to treat previously untreated patients with advanced or metastatic renal cell carcinoma, a type of kidney cancer, failed to meet one of the main goals of a late-stage trial.

BRIEF-Bristol-Myers Squibb announces topline results

* Bristol-Myers Squibb announces topline results from checkmate -214, a phase 3 study of opdivo in combination with yervoy in intermediate and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma

BRIEF-Regen Biopharma addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics

* Regen Biopharma Inc addresses potential impact of recent Bristol Myers Squibb's $2.3 billion acquisition of IFM Therapeutics Source text for Eikon: Further company coverage:

Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline

Bristol-Myers Squibb Co said it would buy privately held IFM Therapeutics for an upfront payment of $300 million, as the drugmaker looks to bolster its cancer portfolio after losing ground to Merck & Co's rival treatment Keytruda.

Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline

Aug 3 Bristol-Myers Squibb Co said it would buy privately held IFM Therapeutics for an upfront payment of $300 million, as the drugmaker looks to bolster its cancer portfolio after losing ground to Merck & Co's rival treatment Keytruda.

BRIEF-Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity

* Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity

BRIEF-Seattle Genetics to buy Bothell plant from Bristol-Myers Squibb

* Seattle Genetics announces purchase of Bothell manufacturing facility from Bristol-Myers Squibb

BRIEF-Bristol-Myers Squibb receives FDA approval for opdivo

* Bristol-Myers Squibb receives FDA approval for opdivo (nivolumab) in MSI-H or DMMR metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan

Select another date: